VI 0162

Drug Profile

VI 0162

Latest Information Update: 18 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VIVUS
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Premature ejaculation

Most Recent Events

  • 18 Sep 2006 Discontinued - Phase-I for Premature ejaculation in USA (PO)
  • 30 Jun 2003 VIVUS has completed a phase I at-home trial in premature ejaculation in the USA
  • 25 Nov 2002 Phase-I clinical trials in Premature ejaculation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top